Načítá se...
A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN’S PATIENTS REFRACTORY TO ANTI-TNF THERAPY
BACKGROUND: Patients with moderate to severe Crohn’s disease refractory or intolerant to steroids, immunomodulators and anti-TNF therapy currently have few options for medical management outside of clinical trials. Ustekinumab, a monoclonal antibody, which inhibits interleukins 12 and 23 is currentl...
Uloženo v:
| Vydáno v: | J Can Assoc Gastroenterol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507952/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.127 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|